Table 1.

Patient-reported outcomes at baseline. Modified intent-to-treat population, observed case. Data are mean (SD).

CharacteristicsETN 50 mg QW, n = 106PBO, n = 109
General well-being/fatigue/pain
  BAS-G, 0–106.3 (1.8)6.3 (1.7)
  BAS-G since last week, 0–106.0 (2.1)6.0 (2.1)
  Nocturnal back pain, 0–10 VAS5.5 (2.6)5.4 (2.5)
  Average back pain, 0–10 VAS5.5 (2.4)5.4 (2.3)
  MFI, 4–20
    General fatigue14.7 (3.5)15.0 (3.5)
    Mental fatigue10.9 (3.8)10.5 (3.7)
    Physical fatigue14.0 (3.9)13.6 (3.8)
    Reduced activity11.4 (3.8)11.8 (3.8)
    Reduced motivation9.6 (3.2)8.9 (3.4)
Utility/HRQOL
  EQ-5D, 0–100 VAS56.5 (21.0)56.4 (20.6)
  EQ-5D utility score, 0–10.5 (0.3)0.6 (0.3)
  SF-36, 0–100
    PCS37.8 (8.9)37.2 (8.1)
    MCS42.3 (11.9)43.5 (11.1)
  ASQOL, 0–188.6 (4.8)8.4 (4.8)
Work productivity
  WPAI-AS, 0–100%
    Absenteeism, % work time missed*9.1 (25.0)11.8 (27.7)
    Presenteeism, % impairment while working*44.9 (26.7)42.2 (26.3)
    Overall work impairment, %*45.0 (26.2)43.9 (27.8)
    Activity impairment, %53.2 (25.9)52.1 (24.3)
  AS WIS, 0–2012.4 (5.2)12.5 (5.2)
Sleep/anxiety/depression
    MOS sleep scale I, 0–10043.9 (17.6)46.2 (17.4)
    MOS sleep scale II, 0–10045.5 (17.7)48.1 (17.4)
    HADS anxiety, 0–216.6 (4.1)6.8 (4.0)
    HADS depression, 0–215.9 (4.1)5.6 (4.1)
  • * Employed patients at baseline (ETN, n = 66; PBO, n = 63). ETN: etanercept; PBO: placebo; BAS-G: Bath Ankylosing Spondylitis Patient Global Score; VAS: visual analog scale; MFI: Multidimensional Fatigue Inventory; HRQOL: health-related quality of life; MOS: Medical Outcomes Study; SF-36: MOS Short Form-36; PCS: physical component summary; MCS: mental component summary; AS: ankylosing spondylitis; ASQOL: AS quality of life; WPAI-AS: Work Productivity and Activity Index in AS; AS WIS: Work Instability Scale for AS; HADS: Hospital Anxiety and Depression Scale; QW: once weekly.